Circulating tumour DNA (ctDNA) variants can be detected in patients with oesophageal adenocarcinoma (OAC) and may have prognostic significance in a complex disease with typically poor survival.
A Queensland study performed whole-genome and exome sequencing on pre- and post-treatment plasma samples and tissue biopsies obtained perioperatively in 57 patients with locally advanced, resectable OAC.
The study, published in ESMO Open Cancer Horizons, found ctDNA variants in 38% of patients and a total of 90 ctDNA variants (range 0–7 per sample) in pre- and post-therapy plasma samples.
TP53 was the most frequently mutated gene in patients with detectable variants (45%).
The study said the detection of one or two ctDNA variants was significantly associated with disease-specific survival (DSS).
It found ctDNA-positive patients had significantly worse DSS (median 58.8 months) and a trend towards worse PFS (median 23 months) when compared with ctDNA-negative patients (median DSS and median PFS not reached).
The study also found that ‘shedders’, where ctDNA variants in plasma were verified by the primary tumour genomic profile, had worse DSS and worse PFS than ‘non-shedders’ (primary tumour variants not detected in plasma) and patients with no variant detected in their primary tumour.
The study, led by Dr Vanessa Bonazzi from the University of Queensland Diamantina Institute, said it had demonstrated the utility of ctDNA as a clinical marker in OAC which is characterised by intratumour heterogeneity (ITH).
“We showed that when only one tumour biopsy was sequenced, only [a] few variants were identified in both ctDNA and the tumour, most likely due to ITH. When we sequenced multiple biopsies from each patient, there was greater concordance between the tumour and ctDNA genomic profiles,” it said.
“This suggests that tumours may not shed ctDNA homogenously across the tumour mass, and raises the question of whether only certain sub-clones shed ctDNA.”